A Cost-Benefit Analysis of the Medicines Patent Pool

Wang, Lucy Xiaolu

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Paper

A Cost-Benefit Analysis of the Medicines Patent Pool

MPS-Authors

/persons/resource/persons249093

Wang, Lucy Xiaolu
MPI for Innovation and Competition, Max Planck Society;

External Resource

http://dx.doi.org/10.2139/ssrn.4262457
(Preprint)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Wang, L. X. (2023). A Cost-Benefit Analysis of the Medicines Patent Pool. Max Planck Institute for Innovation & Competition Research Paper, No. 23-18.

Cite as: https://hdl.handle.net/21.11116/0000-000D-9F99-4

Abstract

Understanding the cost and benefit of global public health institutions is important but challenging. This study provides a cost-benefit analysis of the first public health-oriented patent pooling and licensing institution, the Medicines Patent Pool (MPP), which is devoted to improving generic drug licensing and supply in low- and middle-income countries. A simple structural model of demand and supply is estimated on a dataset that covers 103 LMIC and 29 HIV drugs with data on sales, MPP licenses, patents, country-year level diseases and demographics, and institutional factors during 2007-2017. Counterfactuals are simulated in the absence of the MPP or with further expansions. The estimated benefits to consumers and firms far exceed the operating costs.